Pancreas Transplant: (Pancreas Transplant Alone, Pancreas Transplant after Kidney Transplant, Simultaneous Pancreas Kidney Transplant): Islet Cell Transplant 7.02.01
Summary
Excellus BlueCross BlueShield policy 07.02.01 covers pancreas transplant alone for insulin-dependent diabetes that is difficult to manage, when the patient has had frequent, acute, and severe metabolic complications requiring medical attention, consistent failure of insulin-based management, and no advanced kidney disease (stage IV or V). Pancreas transplant after kidney transplant and simultaneous pancreas-kidney transplant are considered medically appropriate under listed criteria. A second pancreas transplant after a failed primary transplant is considered medically appropriate for individuals who still meet transplant criteria. Autologous islet cell transplantation is considered medically appropriate as an adjunct to total or near-total pancreatectomy in chronic pancreatitis. Allogeneic islet cell transplantation with FDA-approved donislecel-jujn (Lantidra) is considered investigational for type 1 diabetes. This version is effective March 19, 2026.
Get alerts when payers change rules like this one
We check Excellus BlueCross BlueShield and other payers every day and email you when a change matches your specialty and state.